Molecular Genetics of Argininosuccinic Aciduria

Abstract

Argininosuccinic aciduria is an autosomal recessive disorder of the urea cycle caused by mutations in argininosuccinate lyase (ASL). Two main clinical phenotypes are reported: an acute neonatal form characterised by severe hyperammonaemia and coma, and a subacute, late‐onset form which may present with relatively milder neurological symptoms.

More than 120 ASL mutations have been reported so far: the majority are missense, but virtually all types of point mutations are found. Large rearrangements are rare and standard genomic deoxyribonucleic acid (DNA) analysis has a high diagnostic yield.

Genotype–phenotype correlations have been difficult to establish as standard biochemical techniques are not sufficiently sensitive to measure residual activity, and other factors such as intragenic complementation, overexpression of nonfunctional ASL transcripts and environmental factors may modulate the phenotype.

Clinical manifestations result from the block in the urea cycle and also from impairment of nitric oxide biosynthesis, and the therapy is aimed at restoring these two functions.

Key Concepts:

  • Argininosuccinic aciduria is caused by deficiency of argininosuccinate lyase (ASL).

  • ASL is a component of the urea cycle and is essential for detoxification of ammonia, and for the synthesis of arginine and nitric oxide (NO).

  • Two clinical forms of argininosuccinic aciduria exist: an acute, potentially lethal, neonatal onset disease and a milder, late‐onset form.

  • More than 120 ASL mutations have been described but the exact genotype/phenotype correlations are still not completely clear.

  • Other factors (genetic and environmental) may influence the clinical phenotype.

  • Treatment is based on protein restriction, arginine, nitrogen scavengers and NO donors.

Keywords: urea cycle; argininosuccinate lyase; nitric oxide; hyperammonaemia; intragenic complementation; molecular diagnosis; animal models

Figure 1.

(a) Structure of the ASL tetramer. Arrowheads indicate the active sites. In yellow is argininosuccinic acid. (b) Structure of the ASL monomer with the three domains depicted in different colours.

Figure 2.

(a) Heterotetramer formed by the p.R113Q and p.Q286R mutants. Arrowheads indicate mutant residues (which are represented in red). The yellow circles indicate ‘normal’ active sites; the red circles indicate active sites containing mutant residues. (b) Heterotetramer formed by the p.R113Q and p.R236W mutants. No ‘normal’ active sites can be formed. (c) Position of residues arginine 113, arginine 236 and glutamine 286 within the different ASL domains. In pink is the substrate (ASA).

close

References

Abramson RD, Barbosa P, Kalumuck K and O'Brien WE (1991) Characterization of the human argininosuccinate lyase gene and analysis of exon skipping. Genomics 10: 126–132.

Ah Mew N, Krivitzky L, McCarter R, Batshaw M and Tuchman M (2013) Clinical outcomes of neonatal onset proximal versus distal urea cycle disorders do not differ. Journal of Pediatrics 162: 324–329, e1.

Al‐Sayed M, Alahmed S, Alsmadi O et al. (2005) Identification of a common novel mutation in Saudi patients with argininosuccinic aciduria. Journal of Inherited Metabolic Disease 28: 877–883.

Allan JD, Cusworth DC, Dent CE and Wilson VK (1958) A disease, probably hereditary characterised by severe mental deficiency and a constant gross abnormality of aminoacid metabolism. Lancet 1: 182–187.

Balmer C, Pandey AV, Rufenacht V et al. (2014) Mutations and polymorphisms in the human argininosuccinate lyase (ASL) gene. Human Mutation 35: 27–35.

Barbosa P, Wistow GJ, Cialkowski M, Piatigorsky J and O'Brien WE (1991) Expression of duck lens delta‐crystallin cDNAs in yeast and bacterial hosts. Delta 2‐crystallin is an active argininosuccinate lyase. Journal of Biological Chemistry 266: 22319–22322.

Brunetti‐Pierri N, Erez A, Shchelochkov O, Craigen W and Lee B (2009) Systemic hypertension in two patients with ASL deficiency: a result of nitric oxide deficiency? Molecular Genetics and Metabolism 98: 195–197.

Chadefaux B, Ceballos I, Rabier D et al. (1990) Prenatal diagnosis of argininosuccinic aciduria by assay of argininosuccinate in amniotic fluid at the 12th week of gestation. American Journal of Medical Genetics 35: 594.

Christodoulou J, Craig HJ, Walker DC et al. (2006) Deletion hotspot in the argininosuccinate lyase gene: association with topoisomerase II and DNA polymerase alpha sites. Human Mutation 27: 1065–1071.

Cooper DN and Youssoufian H (1988) The CpG dinucleotide and human genetic disease. Human Genetics 78: 151–155.

Doimo M, Trevisson E, Sartori G, Burlina A and Salviati L (2012) Yeast complementation is sufficiently sensitive to detect the residual activity of ASL alleles associated with mild forms of argininosuccinic aciduria. Journal of Inherited Metabolic Disease 35: 557–558.

Engel K, Vuissoz JM, Eggimann S et al. (2011) Bacterial expression of mutant argininosuccinate lyase reveals imperfect correlation of in‐vitro enzyme activity with clinical phenotype in argininosuccinic aciduria. Journal of Inherited Metabolic Disease 35: 133–140.

Erez A (2013) Argininosuccinic aciduria: from a monogenic to a complex disorder. Genetics in Medicine 15: 251–257.

Erez A, Nagamani SC, Shchelochkov OA et al. (2011) Requirement of argininosuccinate lyase for systemic nitric oxide production. Nature Medicine 17: 1619–1626.

Fleisher LD, Rassin DK, Desnick RJ et al. (1979) Argininosuccinic aciduria: prenatal studies in a family at risk. American Journal of Human Genetics 31: 439–445.

Hu L, Pandey AV, Eggimann S et al. (2013) Understanding the role of argininosuccinate lyase transcript variants in the clinical and biochemical variability of the urea cycle disorder argininosuccinic aciduria. Journal of Biological Chemistry 288: 34599–34611.

Keskinen P, Siitonen A and Salo M (2008) Hereditary urea cycle diseases in Finland. Acta Paediatrica 97: 1412–1419.

Kleijer WJ, Garritsen VH, Linnebank M et al. (2002) Clinical, enzymatic, and molecular genetic characterization of a biochemical variant type of argininosuccinic aciduria: prenatal and postnatal diagnosis in five unrelated families. Journal of Inherited Metabolic Disease 25: 399–410.

Linnebank M, Tschiedel E, Haberle J et al. (2002) Argininosuccinate lyase (ASL) deficiency: mutation analysis in 27 patients and a completed structure of the human ASL gene. Human Genetics 111: 350–359.

Nagamani SC, Campeau PM, Shchelochkov OA et al. (2012a) Nitric‐oxide supplementation for treatment of long‐term complications in argininosuccinic aciduria. American Journal of Human Genetics 90: 836–846.

Nagamani SC, Erez A and Lee B (2012b) Argininosuccinate lyase deficiency. Genetics in Medicine 14: 501–507.

Nagamani SC, Lee B and Erez A (2012c) Optimizing therapy for argininosuccinic aciduria. Molecular Genetics and Metabolism 107: 10–14.

O'Brien WE, McInnes R, Kalumuck K and Adcock M (1986) Cloning and sequence analysis of cDNA for human argininosuccinate lyase. Proceedings of the National Academy of Sciences of the USA 83: 7211–7215.

Sampaleanu LM, Vallee F, Slingsby C and Howell PL (2001) Structural studies of duck delta 1 and delta 2 crystallin suggest conformational changes occur during catalysis. Biochemistry 40: 2732–2742.

Tanaka T, Nagao M, Mori T and Tsutsumi H (2002) A novel stop codon mutation (X465Y) in the argininosuccinate lyase gene in a patient with argininosuccinic aciduria. Tohoku Journal of Experimental Medicine 198: 119–124.

Trevisson E, Burlina A, Doimo M et al. (2009) Functional complementation in yeast allows molecular characterization of missense argininosuccinate lyase mutations. Journal of Biological Chemistry 284: 28926–28934.

Trevisson E, Salviati L, Baldoin MC et al. (2007) Argininosuccinate lyase deficiency: mutational spectrum in Italian patients and identification of a novel ASL pseudogene. Human Mutation 28: 694–702.

Tuchman M, Lee B, Lichter‐Konecki U et al. (2008) Cross‐sectional multicenter study of patients with urea cycle disorders in the United States. Molecular Genetics and Metabolism 94(4): 397–402.

Yu B and Howell PL (2000) Intragenic complementation and the structure and function of argininosuccinate lyase. Cellular and Molecular Life Sciences 57: 1637–1651.

Zimmermann A, Bachmann C and Baumgartner R (1986) Severe liver fibrosis in argininosuccinic aciduria. Archives of Pathology and Laboratory Medicine 110: 136–140.

Further Reading

Brusilow S and Horwich A (2001) Urea cycle enzymes. In: Scriver C , Beaudet A , Sly W , Valle D (eds) The Metabolic & Molecular Bases of Inherited Disease, pp. 1909–1963. New York: McGraw‐Hill.

Contact Editor close
Submit a note to the editor about this article by filling in the form below.

* Required Field

How to Cite close
Trevisson, Eva, Doimo, Mara, and Salviati, Leonardo(May 2014) Molecular Genetics of Argininosuccinic Aciduria. In: eLS. John Wiley & Sons Ltd, Chichester. http://www.els.net [doi: 10.1002/9780470015902.a0025353]